Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
about
MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.Multi-drug delivery to tumor cells via micellar nanocarriersPharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycinAntitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.HSP90 Inhibitors, Geldanamycin and Radicicol, Enhance Fisetin-Induced Cytotoxicity via Induction of Apoptosis in Human Colonic Cancer Cells.A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.Targeting the mTOR pathway using deforolimus in cancer therapy.Small molecules and targeted therapies in distant metastatic disease.Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.Insights from yeast into whether the inhibition of heat shock transcription factor (Hsf1) by rapamycin can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor.Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.Triolimus: A Multi-Drug Loaded Polymeric Micelle Containing Paclitaxel, 17-AAG, and Rapamycin as a Novel Radiosensitizer.Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
P2860
Q34354215-1AC8ACAB-B82E-4F0B-A8F1-2354AAF7C3EEQ35269272-2497F205-9B87-4033-8F0F-686508DFBF0EQ36174463-47F58E8E-2866-4F78-8B6A-03AAC1D5EAB8Q36312850-F3F054B0-2509-4554-A93B-0CD50FB8011BQ36956034-BDC0CB5C-A78D-4E26-B8FD-ED60102ABFE7Q36976738-6F7B2509-3E9F-49CB-926E-B78331638B5DQ37362480-F19459AC-0366-4E66-94B4-5AA9B8EF28F5Q37448927-7E60DCD2-E2D7-4AE2-8F93-07F1F5507D40Q37555793-6AB7ADDD-5F83-456A-95A1-D1F88CD79B51Q37714232-A652132B-D6B1-48D7-B6F6-29580EA6D472Q39122639-89C2F3B8-A38E-438B-98E3-14189CC62877Q41899062-A935B7C0-2C7F-4286-BE85-1A7CC9ECFC73Q50238528-53A0AAB4-BC52-4480-B73F-50374635BD88Q51670941-3D1B1E03-5FE6-40AE-85F8-3ACA460EEA9DQ51754497-EC6B9BC0-7717-429F-B337-AB8AC2E69724Q53059131-322852F8-87C5-4815-AB8B-6BB9644BA1F5
P2860
Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@en
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@nl
type
label
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@en
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@nl
prefLabel
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@en
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@nl
P1433
P1476
Combination of rapamycin and 1 ...... ockade in breast cancer cells.
@en
P2093
Chalet Tan
Matthew M Roforth
P304
P356
10.1097/CAD.0B013E3283067681
P577
2008-08-01T00:00:00Z